Special focus issue: passive immunization

References

• Gonzalez-Quintela A, Alende R, Gude F, Campos J, Rey J, Meijide LM, Fernandez-Merino C, Vidal C. Serum levels of immunoglobulins (IgG, IgA, IgM) in a general adult population and their relationship with alcohol consumption, smoking and common metabolic abnormalities. Clin Exp Immunol. 2008;151(1):1–3. doi:https://doi.org/10.1111/j.1365-2249.2007.03545.x.
   PubMedGoogle Scholar
• Feige MJ, Grawert MA, Marcinowski M, Hennig J, Behnke J, Auslander D, Herold EM, Peschek J, Castro CD, Flajnik M, et al. The structural analysis of shark IgNAR antibodies reveals evolutionary principles of immunoglobulins. Proc Natl Acad Sci U S A. 2014;111(22):8155–60. doi:https://doi.org/10.1073/pnas.1321502111.
   PubMed Web of Science ®Google Scholar
• von Behring E, Kitasato S. The mechanism of diphtheria immunity and tetanus immunity in animals. 1890. Mol Immunol. 1991;28:1317, 1319–1320.
   Google Scholar
• Casadevall A, Dadachova E, Pirofski LA. Passive antibody therapy for infectious diseases. Nat Rev Microbiol. 2004;2(9):695–703. doi:https://doi.org/10.1038/nrmicro974.
   PubMed Web of Science ®Google Scholar
• Enria DA, Briggiler AM, Fernandez NJ, Levis SC, Maiztegui JI. Importance of dose of neutralising antibodies in treatment of Argentine haemorrhagic fever with immune plasma. Lancet. 1984;2(8397):255–56. doi:https://doi.org/10.1016/S0140-6736(84)90299-X.
   PubMed Web of Science ®Google Scholar
• Lee JS, Adhikari NKJ, Kwon HY, Teo K, Siemieniuk R, Lamontagne F, Chan A, Mishra S, Murthy S, Kiiza P, et al. Anti-Ebola therapy for patients with Ebola virus disease: a systematic review. BMC Infect Dis. 2019;19(1):376. doi:https://doi.org/10.1186/s12879-019-3980-9.
   PubMedGoogle Scholar
• Zeitlin L, Whaley KJ, Olinger GG, Jacobs M, Gopal R, Qiu X, Kobinger GP. Antibody therapeutics for Ebola virus disease. Curr Opin Virol. 2016;17:45–49. doi:https://doi.org/10.1016/j.coviro.2016.01.006.
   PubMed Web of Science ®Google Scholar
• Snow TAC, Saleem N, Ambler G, Nastouli E, McCoy LE, Singer M, Arulkumaran N. Convalescent plasma for COVID-19: a meta-analysis, trial sequential analysis, and meta-regression. Br J Anaesth. 2021;127:834–44. doi:https://doi.org/10.1016/j.bja.2021.07.033.
   PubMedGoogle Scholar
• Tharmalingam T, Han X, Wozniak A, Saward L. Polyclonal hyper immunoglobulin: a proven treatment and prophylaxis platform for passive immunization to address existing and emerging diseases. Hum Vaccin Immunother. 2021:1–20. doi:https://doi.org/10.1080/21645515.2021.1886560.
   Google Scholar
• Hansda A, Biswas D, Bhatta A, Chakravorty N, Mukherjee G. Plasma therapy: a passive resistance against the deadliest. Hum Vaccin Immunother. 2021:1–10. doi:https://doi.org/10.1080/21645515.2021.2006026.
   Google Scholar
• Sano A, Matsushita H, Wu H, Jiao JA, Kasinathan P, Sullivan EJ, Wang Z, Kuroiwa Y. Physiological level production of antigen-specific human immunoglobulin in cloned transchromosomic cattle. PloS One. 2013;8(10):e78119. doi:https://doi.org/10.1371/journal.pone.0078119.
   PubMedGoogle Scholar
• Liu Z, Wu H, Egland KA, Gilliland TC, Dunn MD, Luke TC, Sullivan EJ, Klimstra WB, Bausch CL, Whelan SP. Human immunoglobulin from transchromosomic bovines hyperimmunized with SARS-CoV-2 spike antigen efficiently neutralizes viral variants. Hum Vaccin Immunother. 2021:1–10. doi:https://doi.org/10.1080/21645515.2021.1940652.
   Google Scholar
• Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256(5517):495–97. doi:https://doi.org/10.1038/256495a0.
   PubMed Web of Science ®Google Scholar
• Smith SL. Ten years of Orthoclone OKT3 (muromonab-CD3): a review. J Transplant Coord. 1996;6(3):109–119; quiz 120–101. doi:https://doi.org/10.7182/prtr.1.6.3.8145l3u185493182.
   Google Scholar
• Wu H, Pfarr DS, Losonsky GA, Kiener PA. Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab. Curr Top Microbiol Immunol. 2008;317:103–23. doi:https://doi.org/10.1007/978-3-540-72146-8_4.
   PubMed Web of Science ®Google Scholar
• Wellcome Trust & IAVI. Expanding access to monoclonal antibody-based products: a global call to action; 2020 [accessed 2021 Nov 19]. https://wellcome.org/sites/default/files/expanding-access-to-monoclonal-antibody-based-products.pdf.
   Google Scholar
• Whaley KJ, Zeitlin L. Emerging antibody-based products for infectious diseases: planning for metric ton manufacturing. Hum Vaccin Immunother. 2021.
   PubMedGoogle Scholar
• Truong VL, Jafri H, Francois B. Clinical experience with human monoclonal antibodies for bacterial pathogens. Hum Vaccin Immunother. 2021.
   Google Scholar
• Gunn BM, Bai S. Building a better antibody through the Fc: advances and challenges in harnessing antibody Fc effector functions for antiviral protection. Hum Vaccin Immunother. 2021;17(11):4328–44. doi:https://doi.org/10.1080/21645515.2021.1976580.
   PubMedGoogle Scholar
• Zeitlin L, Cone RA, Moench TR, Whaley KJ. Preventing infectious disease with passive immunization. Microbes Infect. 2000 May;2(6):701–08. doi:https://doi.org/10.1016/s1286-4579(00)00355-5. PMID: 10884621.
   PubMed Web of Science ®Google Scholar
• Kremer J, Jager S. The significance of antisperm antibodies for sperm-cervical mucus interaction. Hum Reprod. 1992 Jul;7(6):781–84. doi:https://doi.org/10.1093/oxfordjournals.humrep.a137737. PMID: 1500475.
   PubMed Web of Science ®Google Scholar
• Kremer J, Jager S. The sperm-cervical mucus contact test: a preliminary report. Fertil Steril. 1976 Mar;27(3):335–40. doi:https://doi.org/10.1016/s0015-0282(16)41726-7. PMID: 1254029.
   PubMedGoogle Scholar
• Mestecky J. Antibody-dependent passive protection of mucosal surfaces. Hum Vaccin Immunother. 2021:1–4. doi:https://doi.org/10.1080/21645515.2021.1899549.
   Google Scholar
• Anderson DJ. Passive immunization of the human vagina. Hum Vaccin Immunother. 2021:1–6. doi:https://doi.org/10.1080/21645515.2021.1965423.
   Google Scholar
• Wang YY, Kannan A, Nunn KL, Murphy MA, Subramani DB, Moench T, Cone R, Lai SK. IgG in cervicovaginal mucus traps HSV and prevents vaginal herpes infections. Mucosal Immunol. 2014 Sep;7(5):1036–44. doi:https://doi.org/10.1038/mi.2013.120. Epub 2014 Feb 5.2014 Sep;7(5):1036-44.
   PubMedGoogle Scholar
• Schaefer A, Lai SK. The biophysical principles underpinning muco-trapping functions of antibodies. Hum Vaccin Immunother. 2021:1–10. doi:https://doi.org/10.1080/21645515.2021.1939605.
   Google Scholar
• Olmsted SS, Padgett JL, Yudin AI, Whaley KJ, Moench TR, Cone RA. Diffusion of macromolecules and virus-like particles in human cervical mucus. Biophys J. 2001 Oct;81(4):1930–37. doi:https://doi.org/10.1016/S0006-3495(01)75844-4. PMID: 11566767; PMCID:PMC1301668.
   PubMed Web of Science ®Google Scholar
• Hickey AJ, Stewart IE. Inhaled antibodies: quality and performance considerations 2021. Hum Vaccin Immunother. 2021:1–10. doi:https://doi.org/10.1080/21645515.2021.1940650.
   Google Scholar
• Richards A, Baranova D, Mantis NJ. The prospect of orally administered monoclonal secretory IgA (SIgA) antibodies to prevent enteric bacterial infections. Hum Vaccin Immunother. 2021:1–8. doi:https://doi.org/10.1080/21645515.2021.1964317.
   Google Scholar
• Phalipon A, Cardona A, Kraehenbuhl JP, Edelman L, Sansonetti PJ, Corthésy B. Secretory component: a new role in secretory IgA-mediated immune exclusion in vivo. Immunity. 2002 Jul;17(1):107–15. doi:https://doi.org/10.1016/s1074-7613(02)00341-2. PMID:12150896.
   PubMed Web of Science ®Google Scholar